Novel agents in the treatment of non-small cell lung cancer: Implications for neoadjuvant chemotherapy?

In Vivo

Volumn 19, Issue 3, 2005, Pages 523-534

  Bergqvist, Michael ^a   Henriksson, Roger ^b   Brattström, Daniel ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anti angiogenesis inhibitors; Cisplatin; EGFR inhibiting agents; Gemcitabine; Lung cancer; Neoadjuvant chemotherapy; NSCLC; Pemetrexed; Review

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; COMBRETASTATIN; CYANOCOBALAMIN; DEXAMETHASONE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; ETOPOSIDE; FOLIC ACID; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MITOMYCIN; NAVELBINE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PEMETREXED; PRINOMASTAT; REBIMASTAT; SQUALAMINE; TANOMASTAT; UNINDEXED DRUG;

ADVANCED CANCER; ALOPECIA; ANAPHYLAXIS; ANEMIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BLEEDING; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; GRANULOCYTOPENIA; HEMOPTYSIS; HUMAN; INFECTION; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MOTOR NEUROPATHY; MUSCULOSKELETAL DISEASE; NAIL DISEASE; NAUSEA; NEUTROPENIA; NONHUMAN; QUALITY OF LIFE; REVIEW; SKIN TOXICITY; THROMBOCYTOPENIA; VOMITING;

EID: 17644363305     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Minna JD, Fong K, Zochbauer-Muller S and Gazdar AF: Molecular pathogenesis of lung cancer and potential translational applications. Cancer J 8 Suppl 1: S41-46, 2002.
2. Boyle P: Cancer, cigarette smoking and premature death in Europe: a review including the Recommendations of European Cancer Experts Consensus Meeting, Helsinki, October 1996. Lung Cancer 17(1): 1-60, 1997.
3. Scagliotti G: Consensus development conference on the medical treatment of non-small cell lung cancer: treatment of the early stages. Lung Cancer 38(3 Suppl): 23-29, 2002,
4. Nesbitt JC, Putnam JB Jr, Walsh GL, Roth JA and Mountain CF: Survival in early-stage non-small cell lung cancer. Ann Thorac Surg 60(2): 466-472, 1995.
5. Deslauriers J, Ginsberg RJ, Dubois P, Beaulieu M, Goldberg M and Piraux M: Current operative morbidity associated with elective surgical resection for lung cancer. Can J Surg 32(5): 335-339, 1989.
6. Rosell R, Gomez-Codina J, Camps C, Javier Sanchez J, Maestre J, Padilla J, Canto A, Abad A and Roig J: Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 26(1): 7-14, 1999.
7. Roth JA, Atkinson EN, Fossella F, Komaki R, Bernadette Ryan M, Putnam JB, Jr., Lee JS, Dhingra H, De Caro L, Chasen M and Hong WK: Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 21(1): 1-6, 1998.
8. Pass HI, Pogrebniak HW, Steinberg SM, Mulshine J and Minna J: Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg 53(6): 992-998, 1992.
9. Depierre A, Milleron B, Moro-Sibilot D, Chevret S, Quoix E, Lebeau B, Braun D, Breton JL, Lemarie E, Gouva S, Paillot N, Brechot JM, Janicot H, Lebas FX, Terrioux P, Clavier J, Foucher P, Monchatre M, Coetmeur D, Level MC, Leclerc P, Blanchon F, Rodier JM, Thiberville L, Villeneuve A, Westeel V and Chastang C: Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 20(1): 247-253, 2002.
10. Mattson KV, Abratt RP, ten Velde G and Krofta K: Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: a multinational randomised phase III study. Ann Oncol 14(1) 116-122, 2003.
11. Gutheil JaF: Antimetabolites. In: Perry M, ed. The Chemotherapy Source Book, Third Edition,vol Philadelphia, Lippincott Williams & Wilkins, 208-227, 2001.
12. Postmus PE and Green MR: Overview of MTA in the treatment of non-small cell lung cancer. Semin Oncol 26(1 Suppl 4): 31-36, 1999.
13. Adjei AA: Pemetrexed (Alimta): a novel multitargeted antifolate agent. Expert Rev Anticancer Ther 3(2): 145-156, 2003.
14. Zhao R, Babani S, Gao F, Liu L and Goldman ID: The mechanism of transport of the multitargeted antifolate MTA-LY231514, and its crossresistance pattern in cell with impaired transport of methotrexate. Clin Cancer Res 6: 3687-3695, 2000.
15. Goldman I and Zhao R: Molecular, biochemical, and cellular pharmacology of pemetrexed. Semin Oncol 29: 3-17, 2002.
16. Shih C, Chen VJ, Gosset LS et al: LY23111514, a pyrrolo (2,3-d) pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997(57): 1116-1123, 1997.
17. Rinaldi D, Burris H, Dorr F et al: Initial phase I evaluation of the novel thymidylate synthase inhibitor LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol 17(13): 2842-2850, 1995.
18. McDonald A, Vasey PA, Adams L et al: A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. Clin Cancer Res 4: 605-610, 1998.
19. Nakagawa K, Kudoh S, Matsui K, Negoro N et al: A phase I dose-finding study of pemetrexed supplemented with folic acid and vitamin B12 in Japanese patients with solid tumours. Proc Am Soc Clin Oncol 22: 158, abstract 632, 2003.
20. Hammond LA, Forero M, Forouzesh J et al: Phase I study of pemetrexed (LY231514) with vitamin supplementation in patients with locally advanced or metastatic disease. Proc Am Soc Clin Oncol 22: 133, abstract 532, 2003.
21. Awada A, Clark R, Dumez T et al: Phase I trial of pemetrexed plus paclitaxel administered every 21 days in patients with advanced solid tumors. Proc Am Soc Clin Oncol, abstract 2053, 2004.
22. Mackay H, Carmichael J, Glasspol R et al: Phase I study of pemetrexed in combination with docetaxel in patients with advanced solid malignancies. Proc Am Soc Clin Oncol, abstract 2120, 2002.
23. Bolling C, Lubbing T, Graefe S et al: Pemetrexed/gemcitabine/cisplatin: phase I trial in patients with solid tumours. Proc Am Soc Clin Oncol, abstract 3096, 2004.
24. Rusthoven JJ, Eisenhauer E, Butts C, Gregg R, Dancey J, Fisher B and Iglesias J: Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17(4): 1194, 1999.
25. Clarke SJ, Abratt R, Goedhals L, Boyer MJ, Millward MJ and Ackland SP: Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Ann Oncol 13(5): 737-741, 2002.
26. Shepherd FA, Dancey J, Arnold A, Neville A, Rusthoven J, Johnson RD, Fisher B and Eisenhauer E: Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer 92(3): 595-600, 2001.
27. Manegold C, Gatzemeier U, von Pawel J, Pirker R, Malayeri R, Blatter J and Krejcy K: Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial. Ann Oncol 11(4): 435-440, 2000.
28. Koshy S, Herbst RS, Obasaju CK, Fossella F, Papadimitrakopoulou V, Pisters KMW, Blumenschein GR, Peeples BO, Hong WK and Zinner RRG: A phase II trial of pemetrexed (P) plus carboplatin (C) in patients (pts) with advanced non-small-cell lung cancer (NSCLC). ASCO Ann Meet Proc 22: abstract 7074, 2004.
29. Scagliotti G, Kortsik C, Castellano D et al: Phase II randomized study of pemetrexed+carboplatin or oxaliplatin, as front line chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer. Proc Am Soc Clin Oncol, abstract 2513, 625, 2003.
30. Monnerat C, Le Chevalier T, Kelly K et al: Phase II study of pemetrexed-gemcitabine combination in patients with advanced non-small cell lung cancer. Clin Cancer Res 10: 5439-5446, 2004.
31. Adjei A, Nair S, Reuter N et al: Pemetrexed/gemcitabine as front line therapy for advanced NSCLC: a randomized, phase II trial of three schedules. Proc Am Soc Clin Oncol, abstract 7070, 2004.
32. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L and Bunn PA Jr: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22(9): 1589-1597, 2004.
33. Cerny T, Barnes DM, Hasleton P, Barber PV, Healy K, Gullick W and Thatcher N: Expression of epidermal growth factor receptor (EGF-R) in human lung tumours. Br J Cancer 54(2): 265-269, 1986.
34. Rusch V, Klimstra D, Venkatraman E, Pisters PW, Langenfeld J and Dmitrovsky E: Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 3(4): 515-522, 1997.
35. Slichenmyer WJ and Fry DW: Anticancer therapy targeting the erbB family of receptor tyrosine kinases. Semin Oncol 28(5 Suppl 16) 67-79, 2001.
36. Volm M, Rittgen W and Drings P: Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer 77(4): 663-669, 1998.
37. Rosell R, Daniel C, Ramlau R, Szczesna A, Constenla M, Mennecier B, Pfeifer W, Mueser M, Montaner I and Gatzemeier U: Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC). ASCO Ann Meet Proc 22(14) abstr 7012, 2004.
38. Lynch TJ, Lilenbaum R, Bonomi P, Ansari R, Govindan R, Janne PA and Hanna N: A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC). ASCO Ann Meet Proc 22(14): abstr 70084, 2004.
39. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP and Baselga J: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21(12): 2237-2246, 2003.
40. Kris MG, Natale RB, Herbst RS, Lynch TJ, Jr., Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ and Kay AC: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290(16): 2149-2158, 2003.
41. Ochs JS: Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors. Int J Radiat Oncol Biol Phys 58(3): 941-949, 2004.
42. Stahel R, Rossi A, Petruzelka L, Kosimidis P, de Braud F, Bernardo MM, Souquet PJ, Parra HS and Gridelli C: Lessons from the "Iressa" Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations. Br J Cancer 89 Suppl 2: S19-23, 2003.
43. Hidalgo M: Erlotinib: preclinical investigations. Oncology (Huntingt) 17(11 Suppl 12): 11-16, 2003.
44. Shepherd F, Ciuleanu T, Tan H et al: A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. Proc Am Soc Oncol 22: abstract 7022, 2004.
45. Janne PA, Gurubhagavatula S, Yeap BY, Lucca J, Ostler P, Skarin AT, Fidias P, Lynch TJ and Johnson BE: Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. Lung Cancer 44(2): 221-230, 2004.
46. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M and Varmus H: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101(36): 13306-13311, 2004.
47. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE and Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676): 1497-1500, 2004.
48. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J and Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21): 2129-2139, 2004.
49. Cappuzzo F, Magrini E, Ceresoli GL, Bartolini S, Rossi E, Ludovini V, Gregorc V, Ligorio C, Cancellieri A, Damiani S, Spreafico A, Paties CT, Lombardo L, Calandri C, Bellezza G, Tonato M and Crino L: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 96(15): 1133-1141, 2004.
50. Silvestri G, Pritchard R and Welch HG: Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ 317(7161): 771-775, 1998.
51. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A and Johnson DH: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol 22(5): 777-784, 2004.
52. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A and Johnson DH: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 22(5): 785-794, 2004.
53. Herbst RS, Prager D, Hermann R, Miller V, Fehrenbacher L, Hoffman P, Johnson B, Sandler AB, Mass R and Johnson DH: TRIBUTE - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). ASCO Ann Meet Proc 22(14S): abstr 7011, 2004.
54. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, Brennscheidt U, De Rosa F, Mueller B and Von Pawel J: Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). ASCO Ann Meet Proc 22(14S): abstr 7010, 2004.
55. West J, Franklin A, Gumerlock P et al: Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126. Proc Am Soc Oncol, abtract 7014, 2004.
56. Risau W and Flamme I: Vasculogenesis. Annu Rev Cell Dev Biol 11: 73-91, 1995.
57. Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86(3): 353-364, 1996.
58. Klagsbrun M and D'Amore PA: Regulators of angiogenesis. Annu Rev Physiol 53: 217-239, 1991.
59. Folkman J and Shing Y: Angiogenesis. J Biol Chem 267(16) 10931-10934, 1992.
60. Heath EI, O'Reilly S, Humphrey R, Sundaresan P, Donehower RC, Sartorius S, Kennedy MJ, Armstrong DK, Carducci MA, Sorensen JM, Kumor K, Kennedy S and Grochow LB: Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors. Cancer Chemother Pharmacol 48(4): 269-274, 2001.
61. Rigas R, Denham CA, Rinaldi DA, Moore TD, Smith JW, Winston RD, Sridhar KS, Valera S-ZB, Humphrey R and Sorensen JM: Randomized placebo-controlled trials of the matrix metalloproteinase inhibitor (MMPI), BAY12-9566 as adjuvant therapy for patients with small cell and non-small cell lung cancer. Proc Am Soc Clin Oncol 628: abstract 2525, 2003.
62. Naglich JG, Jure-Kunkel M, Gupta E, Fargnoli J, Henderson AJ, Lewin AC, Talbott R, Baxter A, Bird J, Savopoulos R, Wills R, Kramer RA and Trail PA: Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291. Cancer Res 61(23): 8480-8485, 2001.
63. Leighl NB, Shepherd F, Paz-Ares L, Douillard J-Y, Peschel C, Arnold A, Tu D, Galbraith S, Hann K and Seymour L: Randomized phase II-III study of matrix metalloproteinase inhibitor (MMPI) BMS-275291 in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC): NCIC-CTG BR.18. J Clin Oncol, ASCO Ann Meet Proc (Post-Meeting Edition) 22(14S): 7038, 2004.
64. Quirt I, Bodurth A, Lohmann R, Rusthoven J, Belanger I, Young V, Wainman N, Stewar W and Eisenhauer E: Phase II study of marimastat (BB-2516) in malignant melanoma: a clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs 20(4): 431-437, 2002.
65. Shalinsky DR, Brekken J, Zou H, Bloom LA, McDermott CD, Zook S, Varki NM and Appelt K: Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies. Clin Cancer Res 5(7): 1905-1917, 1999.
66. Smylie M, Mercier R, Aboulafia D, Tucker R, Bonomi P, Collier M, Keller MR, Stuart-Smith J, Knowles M, Clendeninn NJ and Shepherd F: Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat in patients having advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 20: 307a (abstract 1226), 2001.
67. Bissett D, von Pawel J, Mercier R, Price A, Nicolson M, Shepherd F, Mazabel E, Penning C, Zhang MH and Collier MA: Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat (P) in combination with gemcitabine (G) and cisplatin (C) in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 21: 296a (abstract 1183), 2002.
68. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M and Ferrara N: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57(20): 4593-4599, 1997.
69. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF, 3rd, Gaudreault J, Damico LA, Holmgren E and Kabbinavar F: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22(11): 2184-2191, 2004.
70. Sandler AB, Blumenschein GR, Henderson T, Lee J, Truong M, Kim E, Mass B, Garcia B, Johnson DH and Herbst RS: Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer. Proc Am Soc Clin Oncol (Post-Meeting Edition) 22(14S): abstract 2000, 2004.
71. Moore KS, Wehrli S, Roder H, Rogers M, Forrest JN Jr, McCrimmon D and Zasloff M: Squalamine: an aminosterol antibiotic from the shark. Proc Natl Acad Sci USA 90(4): 1354-1358, 1993.
72. Sills AK Jr, Williams JI, Tyler BM, Epstein DS, Sipos EP, Davis JD, McLane MP, Pitchford S, Cheshire K, Gannon FH, Kinney WA, Chao TL, Donowitz M, Laterra J, Zasloff M and Brem H: Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature. Cancer Res 58(13): 2784-2792, 1998.
73. Rose V, Schiller J, Wood A, Eskander E, Holroyd K, Desai A, Lee JT, Ahmed M and Kim B: Randomized phase II trial of weekly squalamine, carboplatin, and paclitaxel as first line therapy for advanced non-small cell lung cancer. Proc Am Soc Clin Oncol (Post-Meeting Edition) 22(14S): abstract 7109, 2004.
74. Siemann DW, Chaplin DJ and Horsman MR: Vascular-targeting therapies for treatment of malignant disease. Cancer 100(12): 2491-2499, 2004.
75. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR and Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57(10): 1829-1834, 1997.
76. Hori K, Saito S, Nihei Y, Suzuki M and Sato Y: Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700. Jpn J Cancer Res 90(9): 1026-1038, 1999.
77. Blakey DC, Ashton SE, Westwood FR, Walker M and Ryan AJ: ZD6126: a novel small molecule vascular targeting agent. Int J Radiat Oncol Biol Phys 54(5): 1497-1502, 2002.
78. Blakey DC, Westwood FR, Walker M, Hughes GD, Davis PD, Ashton SE and Ryan AJ: Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 8(6): 1974-1983, 2002.
79. Rosell R, Maestre J, Font A, Moreno I, Molina F, Milla A, Gomez-Codina J and Camps C: A randomized trial of mitomycin/ifosfamide/cisplatin preoperative chemotherapy plus surgery versus surgery alone in stage IIIA non-small cell lung cancer. Semin Oncol 21(3 Suppl 4): 28-33, 1994.
80. Endo C, Saito Y, Iwanami H, Tsushima T, Imai T, Kawamura M, Kondo T, Koike K, Handa M, Kanno R and Fujimura S: A randomized trial of postoperative UFT therapy in p stage I, II non-small cell lung cancer: North-east Japan Study Group for Lung Cancer Surgery. Lung Cancer 40(2): 181-186, 2003.
81. Scagliotti GV, Fossati R, Torri V, Crino L, Giaccone G, Silvano G, Martelli M, Clerici M, Cognetti F and Tonato M: Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst 95(19): 1453-1461, 2003.
82. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP and Vansteenkiste J: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350(4): 351-360, 2004.
83. Winton T, Livingstone R, Johnson J et al: A prospective randomised trial of adjuvant vinorelbine and cisplatin in completely resected stage IB and II non small cell lung cancer intergroup JBR 10. Proc Am Soc Clin Oncol, abstract 7018, 2004.
84. Strauss G, Herdon J, Maddaus M et al: Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer: Report of Cancer and Leukemia Group B (CALGB) protocol 9633. Proc Am Soc Clin Oncol, 2004.